🇺🇸 FDA
Pipeline program

DS-1062a

DS1062-A-U202

Phase 2 small_molecule completed

Quick answer

DS-1062a for Non-small Cell Lung Cancer is a Phase 2 program (small_molecule) at Daiichi Sankyo with 1 ClinicalTrials.gov record(s).

Program details

Company
Daiichi Sankyo
Indication
Non-small Cell Lung Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials